Document:

EX-10.10

 Exhibit 10.10 

EXECUTION VERSION 

OPTION AGREEMENT 

This Option Agreement (this “Agreement”), dated as of June 1, 2016 (the “Effective Date”), is by and between Roivant
Sciences Ltd., a Bermuda exempted company (“Roivant”), and Myovant Sciences Ltd., a Bermuda exempted company previously known as Roivant Endocrinology Ltd. (“Myovant”). Each of RSL and Myovant may be referred to
herein as a “Party” and together as the “Parties”. 
 WHEREAS 

A. Myovant is a subsidiary of RSL created for the development and commercialization of treatments for endocrine-related men’s health and
women’s health diseases or disorders; 
 B. Myovant has entered into that certain License Agreement with Takeda Pharmaceuticals
International AG dated April 29, 2016 (the “Takeda Agreement”) relating to certain compounds and products as potential treatments for endocrine-related men’s health and women’s health diseases or disorders; and 

C. RSL wishes to grant to Myovant, and Myovant wishes to receive, an option to receive an assignment of any agreement that RSL or certain of
its affiliates may enter into through which RSL or such affiliates acquire the rights to certain products for endocrine-related men’s health and women’s health diseases or disorders, subject to the terms and conditions set forth herein.

 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, RSL and Myovant, intending to be legally bound, hereby agree as follows: 
  

	1.	DEFINITIONS 

 1.1 “Affiliate” means any Person,
other than a Party, that directly or indirectly owns, is owned by or is under common ownership with a Party to the extent of at least 50 percent of the equity having the power to vote on or direct the affairs of the entity, and any Person actually
controlled by, controlling, or under common control with a Party; provided, however, for the purposes hereof, Myovant and any majority owned or controlled subsidiary of Myovant shall not be deemed to be an Affiliate of RSL (but such subsidiaries
shall be deemed to be Affiliates of Myovant). 
 1.2 “Competing Product” means any small molecule oral GnRH receptor
antagonist (other than a TAK-385 Licensed Product) for the treatment, prevention, cure, or control of Uterine Fibroids, Endometriosis, or prostate cancer. 

1.3 “Complementary Product” means any pharmaceutical or biopharmaceutical product (other than a TAK-385 Licensed
Product) for the treatment, prevention, cure, or control of Uterine Fibroids or Endometriosis, or for which the primary target Indication is hormone-sensitive prostate cancer. 

  
 1 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 1.4 “Confidential Information” has the meaning ascribed in Section
4.1. 
 1.5 “Confirmation Notice” has the meaning ascribed in Section 3.4(b). 

1.6 “Counterparty” means, with respect to a Collaboration Agreement, any party to such Collaboration Agreement other
than RSL or a Covered Affiliate. 
 1.7 “Covered Affiliate” means any Affiliate of RSL that is not a public company.

 1.8 “Disclosing Party” has the meaning ascribed in Section 4.1. 

1.9 “Endometriosis” means a condition resulting from the presence of endometrial tissue outside the uterus. 

1.10 “Exercise Notice” has the meaning ascribed in Section 3.2. 

1.11 “First Commercial Sale” means the first sale of a TAK-385 Licensed Product by Myovant, its Affiliates, or its
sublicensees to an end user or prescriber for use, consumption, or resale in any of the following countries: [***]. 
 1.12
“Indemnitee” has the meaning ascribed in Section 5.3. 
 1.13 “Indemnitor” has the meaning ascribed
in Section 5.3. 
 1.14 “Losses” has the meaning ascribed in Section 5.1. 

1.15 “Option” has the meaning ascribed in Section 3.1. 

1.16 “Option IP” means any patent rights, know-how, and other intellectual property specifically relating to any
Option Product controlled by RSL or its Covered Affiliates following the Effective Date. 
 1.17 “Option Period”
means the period commencing upon a Qualified IPO and ending two (2) years following the date of First Commercial Sale. 
 1.18
“Option Product” means a Complementary Product (other than a Competing Product) that is the subject of a RSL Collaboration Agreement. 

1.19 “Person” means any individual, corporation, trust, estate, partnership, joint venture, company, association,
governmental bureau or agency, or any other entity regardless of the type or nature thereof. 
 1.20 “Qualified IPO”
means an initial public offering of shares of Myovant’s common stock through which Myovant raises at least [***] and lists Myovant’s common stock on either the NASDAQ or the New York Stock Exchange. 

  
 2 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 1.21 “Receiving Party” has the meaning ascribed in Section 4.1. 

1.22 “Recipient” has the meaning ascribed in Section 4.1. 

1.23 “Reimbursable Costs” means, with respect to a RSL Collaboration Agreement (a) payments made by RSL or the
applicable Covered Affiliate to the Counterparty pursuant to such RSL Collaboration Agreement, and (b) the fully-burdened cost incurred by RSL and its Covered Affiliates to conduct the development of Option Products under such RSL Collaboration
Agreement. For purposes of this definition, the fully-burdened cost includes without limitation: (i) the costs of any materials used in conducting such development; (ii) the salary, stock option plan or other similar plans, benefits (if any)
(including without limitation, medical plans and 401(k) or other retirement plans), or employment taxes (if any) of employees of RSL or any Covered Affiliate involved in conducting such development; (iii) related overhead expenses (including without
limitation cost of facilities and utilities, insurance, and all general support, operational and business services); (iv) any and all licensing fees paid or payable to a Third Party for any intellectual property necessary or useful for the conduct
of such development or resulting commercialization of the applicable Option Product(s) (provided that such intellectual property is transferred or assigned to Myovant in connection with the assignment of such RSL Collaboration Agreement; and (v) any
depreciation, amortization or other cost recovery for financial accounting purposes related to assets of RSL or its Covered Affiliates to the extent such assets are used in conducting such development. 

1.24 “Myovant Indemnitees” has the meaning ascribed in Section 5.1. 

1.25 “Review Period” has the meaning ascribed in Section 3.4(b). 

1.26 “RSL Collaboration Agreement” means any agreement entered into by RSL or a Covered Affiliate (a) alone or with
others, to research (or fund any research), develop, make, use, sell, offer for sale, or import any Complementary Product (other than a Competing Product), or (b) with any Third Party with respect to a license or other acquisition of rights relating
to any Complementary Product (other than a Competing Product). 
 1.27 “RSL Indemnitees” has the meaning ascribed in
Section 5.2. 
 1.28 “TAK-385 Licensed Product” has the meaning ascribed in the Takeda Agreement. 

1.29 “Third Party” means any Person other than RSL, Myovant and their respective Affiliates. 

1.30 “Third Party Claim” has the meaning ascribed in Section 5.1. 

1.31 “Uterine Fibroids” means the condition in which a non-cancerous tumor originates from the uterus. 

 

	2.	RSL COLLABORATION AGREEMENTS 

 2.1 RSL Collaboration
Agreements. During the Option Period, within ten (10) business days following the later of a Qualified IPO or the execution of a RSL Collaboration 

  
 3 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 
Agreement, RSL will provide (or cause the applicable Covered Affiliate to provide) Myovant with a true, correct and legible copy of such RSL Collaboration Agreement. If RSL or the applicable
Covered Affiliate executes any amendments, side letters or other agreements with the Counterparty to such RSL Collaboration Agreement relating to such RSL Collaboration Agreement prior to the expiration of the Option Period, then within ten (10)
business days following the execution of any such document, RSL will provide (or will cause the applicable Covered Affiliate to provide) Myovant with a true, correct and legible copy of such document. 

2.2 Other Agreements. Following RSL’s receipt of an Exercise Notice, RSL will not, and will not permit the applicable
Covered Affiliate to, enter into any amendment to such RSL Collaboration Agreement, nor any side letter or other agreement with the applicable Counterparty relating to such RSL Collaboration Agreement, without Myovant’s prior written consent.

  

	3.	OPTION 

 3.1 Grant of Option. RSL hereby grants, on behalf
of itself and its Covered Affiliates, to Myovant an option to receive an assignment and assume all of RSL’s or the applicable Covered Affiliate’s right, title and interest in and to each RSL Collaboration Agreement and the associated
Option IP (the “Option”), subject to the terms and conditions of this Article 3. 
 3.2 Option Exercise.
Myovant may exercise the Option with respect to a RSL Collaboration Agreement at any time during the Option Period by providing RSL written notice of exercise (the “Exercise Notice”). 

3.3 Termination of Option. If RSL does not receive the Exercise Notice prior to the expiration of the Option Period, then the
Option will terminate and RSL will have no further obligation to Myovant with respect to the applicable RSL Collaboration Agreement and associated Option IP. 

3.4 Effect of Option Exercise. 

(a) Statement of Reimbursable Costs; Other Information. Within [***] days of RSL’s receipt of the Exercise Notice, RSL will
provide (or will cause the applicable Covered Affiliate to provide) Myovant with (i) a statement of all Reimbursable Costs incurred to date under the RSL Collaboration Agreement, and all further Reimbursable Costs reasonably anticipated by RSL or
such Covered Affiliate to be incurred within the next [***] days, together with any supporting documentation reasonably requested by Myovant, (ii) a summary of current development and commercialization programs contemplated by Myovant with respect
to the any Option Product, including a good faith estimate of the Reimbursable Costs that would be incurred by RSL during the next calendar year if such RSL Collaboration is not assigned to Myovant and (iii) to the extent that any documents or
information described in Section 3.5(a) or (b) exists but has not yet been provided to Myovant, such documents and information. 

(b) Assignment of RSL Collaboration Agreement. Upon Myovant’s receipt of the documents and information described in subsection (a)
above, Myovant shall have [***] days (the “Review Period”) to provide RSL with written notice of its confirmation to accept of the RSL Collaboration Agreement (“Confirmation Notice”). Promptly upon the receipt of
the 

  
 4 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 
Confirmation Notice, RSL will assign (or cause the applicable Covered Affiliate to assign) to Myovant all of RSL’s or such Covered Affiliate’s right, title and interest in and to such
RSL Collaboration Agreement. If Myovant fails to provide the Confirmation Notice prior to the expiration of the Review Period, then the Option with respect to such RSL Collaboration Agreement will be deemed to be terminated with the effects set
forth in Section 3.3, but the Options for any other RSL Collaboration Agreements shall not be affected. 
 (c) Assignment of Option
IP. Contemporaneously with the assignment of such RSL Collaboration Agreement, RSL will assign and cause its Covered Affiliates to assign to Myovant all Option IP. 

(d) Reimbursable Costs. Following the assignment of such RSL Collaboration Agreement and Option IP, Myovant will reimburse RSL for one
hundred and ten percent (110%) of RSL’s Reimbursable Costs, as follows: Within [***] days following RSL’s receipt of the Exercise Notice, RSL will provide to Myovant an invoice and accounting of the Reimbursable Costs through such date,
together with any supporting documentation reasonably requested by Myovant, and Myovant will pay such invoices (if undisputed) within [***] days of receipt. Thereafter, RSL will provide to Myovant an invoice and accounting of the Reimbursable Costs
on a monthly basis, together with any supporting documentation reasonably requested by Myovant, and Myovant will pay such invoices (if undisputed) within [***] days of receipt. If Myovant disputes any invoice, the Parties will promptly confer and
attempt to resolve such dispute in good faith. 
 (e) Transition of Option IP. Concurrently with the assignment of a RSL
Collaboration Agreement, the Parties will cooperate to transfer to Myovant as expeditiously as practicable the Option IP and full responsibility for the development and/or commercialization programs for the applicable Option Product, including all
regulatory filings and correspondence, contracts, documentation and databases relating to such Option Product. 
 (f) RSL
Collaboration Agreement. Concurrently with the assignment of a RSL Collaboration Agreement, the Parties will cooperate to transfer to Myovant as expeditiously as practicable all material correspondence relating to the applicable RSL Collaboration
Agreement and all material documentation produced pursuant to such RSL Collaboration Agreement including, without limitation, meeting materials and minutes. 

(g) Option Product Programs. Concurrently with the assignment of a RSL Collaboration Agreement, the Parties will cooperate to transfer
to Myovant as expeditiously as practicable detailed reports regarding the plans and progress of the development and/or commercialization programs for the Option Product, and will respond as promptly as practicable to Myovant’s requests for
clarification or additional information. RSL will provide Myovant with copies of all filings and correspondence with any regulatory authority relating to such Option Product. 

3.5 Access to Books and Records. RSL will maintain, and will cause its Covered Affiliates to maintain, books and records
pertaining to each RSL Collaboration Agreement and will make them available for inspection and audit, at Myovant’s expense, by a mutually acceptable independent certified public accounting firm during normal business hours upon reasonable prior
written notice to RSL. RSL’s obligation to maintain such books and records 

  
 5 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 
shall survive for one (1) year following the later of the expiration of the Option Period, the termination of this Agreement or the completion of all transition activities with respect to each
assigned RSL Collaboration Agreement. 
 3.6 Use of Information. With respect to each RSL Collaboration Agreement, unless and
until Myovant accepts the assignment of such RSL Collaboration Agreement, Myovant will use the information provided under Sections 3.4 and 3.5 solely to evaluate its interest in exercising the Option and accepting the assignment of such RSL
Collaboration Agreement. 
  

	4.	CONFIDENTIALITY 

 4.1 Confidential Information. Except to
the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, and subject to the other applicable terms of this Article 4, the Parties agree that the receiving Party (the “Receiving Party”) will
keep confidential and not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any information or materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or
otherwise) that is disclosed to it by the other Party (the “Disclosing Party”) pursuant to this Agreement, including all information concerning any RSL Collaboration Agreement, Option Products and Option IP, and any other technical
or business information of whatever nature concerning the Disclosing Party or its technology or business (collectively, “Confidential Information” of the Disclosing Party), except that the Receiving Party may disclose Confidential
Information of the Disclosing Party to its Affiliates and its Affiliates’ respective officers, directors, employees, agents, subcontractors and consultants with a need to know such Confidential Information to assist the Receiving Party with the
activities contemplated or required of it by this Agreement (and who will be advised of the Receiving Party’s obligations hereunder and who are bound by confidentiality and non-use obligations with respect to such Confidential Information no
less onerous than those set forth in this Agreement) (each, a “Recipient”). For clarity, all information and materials provided by a Counterparty to RSL or a Covered Affiliate in connection with a RSL Collaboration Agreement is
deemed to be the Confidential Information of RSL, subject to Section 4.6. Notwithstanding the foregoing, the Parties acknowledge the practical difficulty of policing the use of information in the unaided memory of the Receiving Party or its
Recipients, and as such each Party agrees that the Receiving Party will not be liable for the use by any of its Recipients of specific Confidential Information of the Disclosing Party that is retained in the unaided memory of such Recipient;
provided, that (a) such Recipient is not aware that such Confidential Information is the confidential information of Disclosing Party at the time of such use; (b) the foregoing is not intended to grant, and will not be deemed to grant, the
Receiving Party, its Affiliates, or its Recipients (i) a right to disclose the Disclosing Party’s Confidential Information or (ii) a license under any Patents or other intellectual property right of the Disclosing Party; and (c) such Recipient
has not intentionally memorized such Confidential Information for use outside this Agreement. For the purpose of this Article 4, the term “Disclosing Party” will include each Party and its Affiliates and their and its respective
officers, directors, employees, agents, subcontractors and consultants who are directed or authorized to disclose such Party’s or Affiliates’ Confidential Information, and the term “Receiving Party” will include each Party
and its Affiliates. 

  
 6 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 4.2 Exceptions. Notwithstanding Section 4.1, the obligations of Section 4.1
will not apply to any specific Confidential Information that the Receiving Party thereof can demonstrate, in each case by competent evidence: 

(a) was already known to the Receiving Party or any of its Recipients, other than under an obligation of confidentiality, at the time
of disclosure; 
 (b) was generally available to the public or was otherwise part of the public domain at the time of its disclosure
to the Receiving Party; 
 (c) became generally available to the public or otherwise part of the public domain after its disclosure
by the Disclosing Party and other than through any act or omission of the Receiving Party or any of its Recipients in breach of this Agreement; 

(d) was subsequently lawfully disclosed to the Receiving Party or any of its Recipients without any obligation of confidentiality or
non-use by a Person other than the Disclosing Party, and who, to the knowledge of the Receiving Party or such Recipient, did not directly or indirectly receive such information from the Disclosing Party or any of its Affiliates under an obligation
of confidence; or 
 (e) was independently developed by the Receiving Party or any of its Recipients without use of or reference to
any information or materials disclosed by the Disclosing Party. 
 Information specific to the use of certain compounds, methods, conditions or features
will not be deemed to be within the foregoing exceptions merely because such information is embraced by general disclosures in the public domain or in the possession of the Receiving Party or its Recipients. In addition, a combination of information
will not be deemed to fall within the foregoing exceptions, even if all of the components fall within an exception, unless the combination itself and its significance are in the public domain or in the possession of the Receiving Party prior to the
disclosures hereunder. Notwithstanding anything to the contrary herein, neither the act of using information in a clinical trial nor the filing of information with a governmental authority shall, for the purpose of this Article 4, in and of itself
be deemed to place such information in the public domain. 
 4.3 Permitted Disclosures. Notwithstanding the provisions of
Section 4.1 or Section 4.2, the Receiving Party may disclose Confidential Information of the Disclosing Party if and to the extent such disclosure is reasonably necessary or useful in: 

(a) the performance by the Receiving Party of its obligations or exercise of its rights as contemplated by this Agreement;
provided that, wherever reasonable and practicable in the circumstances, the recipient of any such Confidential Information will be subject to obligations of confidentiality and non-use with respect to such Confidential Information
substantially similar to the obligations of confidentiality and non-use of the Receiving Party pursuant to this Article 4; 
 (b)
prosecuting or defending litigation with respect to a Party or its Affiliates; provided that a protective order or any similar measures are sought by such Party with respect to the information to be disclosed, to the extent reasonably possible; 

  
 7 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 (c) complying with applicable laws; or 

(d) disclosure to Third Parties in connection with: 
  

	 	(1)	due diligence or similar investigations by or on behalf of a Third Party in connection with an actual or potential marketing, distribution or supply agreement with, license to, or collaboration with, such Third
Party; 

  

	 	(2)	an actual or potential merger with, or acquisition or investment by, such Third Party; 

  

	 	(3)	performance of any such license, collaboration or merger agreement; and 

  

	 	(4)	disclosure to actual or potential Third Party investors in confidential financing documents; 

provided, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use substantially
similar to the obligations of confidentiality and non-use of the Receiving Party pursuant to this Article 4. 
 4.4 Advance
Notice of Compelled Disclosure. Notwithstanding the foregoing, in the event the Receiving Party or a Recipient is required to make a disclosure of the Disclosing Party’s Confidential Information pursuant to Section 4.3(c) to comply with a
subpoena or other legal order, it shall give reasonable advance notice to the Disclosing Party of such disclosure and give the Disclosing Party a reasonable opportunity to quash such subpoena or order and to obtain a protective order requiring that
the Confidential Information and documents that are the subject of such subpoena or order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which such subpoena or order was issued; provided
that, if such subpoena or order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such subpoena or order will be limited to the Disclosing Party’s Confidential Information that is
legally required to be disclosed in response to such subpoena or order and will still be subject to the restrictions on use set forth in this Article 4. 

4.5 Confidentiality of this Agreement and its Terms. Except as otherwise provided in this Article 4, each Party agrees not to
disclose to any Third Party the existence of this Agreement or the terms and conditions of this Agreement without the prior written consent of the other Party. 

4.6 Effect of Assignment of RSL Collaboration Agreements. If Myovant exercises the Option and accepts the assignment of a RSL
Collaboration Agreement, then all Confidential Information relating to such Collaboration Agreement and the associated Option Products and Option IP will thereafter be deemed to be Myovant’s Confidential Information, such that Myovant will be
deemed to be the Disclosing Party with respect to such Confidential Information and RSL will be deemed to be the Receiving Party with respect to such Confidential Information. 

  
 8 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

	5.	INDEMNIFICATION 

 5.1 Indemnification of Myovant. RSL will
defend, indemnify and hold harmless each of Myovant, its Affiliates, and its and their respective directors, officers and employees (collectively, the “Myovant Indemnitees”) from and against any and all losses, liabilities, damages,
penalties, fines, costs and expenses (including reasonable attorneys’ fees and other expenses of litigation) (“Losses”) from any claims, actions, suits or proceedings brought by a Third Party, including investigation by a
regulatory authority, (each, a “Third Party Claim”) against any Myovant Indemnitee to the extent arising from, based upon or occurring as a result of: (a) the (i) negligence or willful misconduct of or (ii) violation of applicable
laws or regulations by, in each case ((i) and (ii)), RSL or any of its Affiliates or its or their respective subcontractors in conducting any activity relating to an Option Product; or (b) any breach or default by RSL or its Affiliates or their
respective employees, agents or contractors of any of the RSL Collaboration Agreement or of the confidentiality provisions of this Agreement; except that the foregoing indemnification obligations will not apply to the extent any such Third Party
Claim falls within the scope of the indemnification obligations of Myovant set forth in Section 5.2, as to which Third Party Claim each Party will indemnify the other Party to the extent of its liability with respect to the Losses applicable to such
Third Party Claim. 
 5.2 Indemnification of RSL. Myovant will defend, indemnify and hold harmless each of RSL, its
Affiliates, and its and their respective directors, officers and employees (collectively, the “RSL Indemnitees”) from and against any and all Losses from any Third Party Claims against any RSL Indemnitee to the extent arising from,
based on or occurring as a result of: (a) the (i) negligence or willful misconduct of or (ii) violation of applicable laws or regulations by, in each case ((i) and (ii)), Myovant or any of its Affiliates or its or their respective subcontractors in
conducting any activity relating to an Option Product; or (b) any breach or default by Myovant or its Affiliates or their respective employees, agents or contractors of any RSL Collaboration Agreement assigned to Myovant or of the confidentiality
provisions of this Agreement; except that the foregoing indemnification obligations will not apply to the extent any such Third Party Claim falls within the scope of the indemnification obligations of RSL set forth in Section 5.1, as to which Third
Party Claim each Party will indemnify the other Party to the extent of its liability with respect to the Losses applicable to such Third Party Claim. 

5.3 Procedure. A Party that intends to exercise its rights under this Article 5 (the “Indemnitee”) will
promptly notify the indemnifying Party (the “Indemnitor”) in writing of any Third Party Claim in respect of which the Indemnitee intends to exercise such rights. The Indemnitee will provide the Indemnitor with reasonable assistance,
at the Indemnitor’s expense, in connection with the defense of the Third Party Claim. The Indemnitor will have the right to assume and conduct the defense of the Third Party Claim with counsel of its choice. The Indemnitee may participate in
and monitor such defense with counsel of its choice, at its own expense. The Indemnitor will not settle any Third Party Claim without the prior written consent of the Indemnitee, not to be unreasonably conditioned, withheld or delayed, unless the
settlement involves only the payment of money by the Indemnitor and does not involve any admission of liability or wrongdoing on the part of any Myovant Indemnitees or RSL Indemnitees, as applicable. So long as the Indemnitor is defending the Third
Party Claim, the Indemnitee will not settle such Third Party Claim without the prior written consent of the Indemnitor, unless Indemnitee releases Indemnitor for all liability for such settlement. 

  
 9 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

	6.	TERM AND TERMINATION 

 6.1
Term. This Agreement will commence upon the Effective Date and terminate upon the earlier of (a) Myovant ceasing to be a direct or indirect subsidiary of RSL that is controlled by RSL, or (a) expiration of the Option Period. For the purposes
of this Section 6. 1, the word “control” means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of
fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise. 
 6.2 Termination. This
Agreement may be terminated by a Party upon written notice by such Party to the other Party if the other Party is in material breach of this Agreement and has not cured such breach within thirty (30) days after notice from the terminating Party
detailing the specific material breach that is alleged. Any such termination shall become effective at the end of such thirty (30)-day period unless the breaching Party has cured any such breach prior to the end of such period. 

6.3 Survival. Articles 1, 4, 5 and 7 and Sections 3.5, 3.6 and 6.3 will survive any termination of this Agreement. 

 

	7.	GENERAL TERMS 

 7.1 Notices. Any and all
notices, elections, offers, acceptances, and demands permitted or required to be made under this Agreement will be in writing, signed by the Party giving such notice, election, offer, acceptance, or demand and will be delivered personally, by
messenger, courier service, telecopy, first class mail or similar transmission, to the Party, at its address on file with the Party giving such notice, election, offer, acceptance or demand or at such other address as may be supplied in writing. The
date of personal delivery or the date of mailing, as the case may be, will be the date of such notice, election, offer, acceptance, or demand. 

7.2 Force Majeure. If the performance of any part of this Agreement by a Party, or of any obligation under this Agreement, is
prevented, restricted, interfered with, or delayed by reason of any cause beyond the reasonable control of the Party liable to perform, unless conclusive evidence to the contrary is provided, the Party so affected shall, on giving written notice to
the other Parties, be excused from such performance to the extent of such prevention, restriction, interference, or delay, provided that the affected Party will use its reasonable best efforts to avoid or remove such causes of nonperformance and
will continue performance with the utmost dispatch whenever such causes are removed. When such circumstances arise, the Parties will discuss in good faith what, if any, modification of the terms of this Agreement may be required in order to arrive
at an equitable solution. 
 7.3 Successors and Assigns. This Agreement may not be assigned or otherwise conveyed by any Party
without the prior written consent of the other Party; provided, however that such prior written consent will not be required for an assignment to an Affiliate of a Party. This Agreement will be binding on and inure to the benefit of the
Parties hereto and their respective successors, successors in title and assigns to the extent that such assignment is permitted under this Section. 

  
 10 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 7.4 Entire Agreement, Amendments. This Agreement constitutes the entire
agreement between the Parties with respect to the subject matter hereof, and supersedes all prior agreements, understandings, and communications between the Parties, whether oral or written, relating to the same subject matter. No change,
modification, or amendment of this Agreement will be valid or binding on the Parties unless such change or modification will be in writing signed by the Party or Parties against whom the same is sought to be enforced. 

7.5 Remedies Cumulative. The remedies of the Parties under this Agreement are cumulative and will not exclude any other remedies
to which the Party may be lawfully entitled. 
 7.6 Not for the Benefit of Third Parties. This Agreement is for the exclusive
benefit of the Parties to this Agreement and not for the benefit of any Third Party. 
 7.7 Further Assurances. Each Party
hereby covenants and agrees that it will execute and deliver such other documents as may be required to implement any of the provisions of this Agreement. 

7.8 No Waiver. The failure of any Party to insist on strict performance of a covenant hereunder or of any obligation hereunder
will not be a waiver of such Party’s right to demand strict compliance therewith in the future, nor will the same be construed as a novation of this Agreement. 

7.9 Captions. Titles or captions of articles and paragraphs contained in this Agreement are inserted only as a matter of
convenience and for reference, and in no way define, limit, extend, or describe the scope of this Agreement or the intent of any provision hereof. 

7.10 Number and Gender. Whenever required by the context, the singular number will include the plural, the plural number will
include the singular, and the gender of any pronoun will include all genders. 
 7.11 Counterparts. This Agreement may be
executed in multiple copies, each one of which will be an original and all of which will constitute one and the same document, binding on the Parties, and each Party hereby covenants and agrees to execute all duplicates or replacement counterparts
of this Agreement as may be required. 
 7.12 Governing Law and Jurisdiction. This Agreement and the legal relations between
the Parties will be governed by and construed in accordance with the laws of the State of New York, without regard to any conflict of laws rules. The courts located within the state of New York will have exclusive jurisdiction over any and all
disputes between the Parties, whether in law or equity, arising out of or relating to this Agreement and the agreements, instruments and documents contemplated hereby and the Parties consent to and agree to submit to the exclusive jurisdiction of
such courts. Each Party waives and agrees not to assert in any such dispute, to the fullest extent permitted by applicable law, any claim that (a) such Party is not personally subject to the jurisdiction of such courts, (b) such Party and such
Party’s property is immune from any legal process issued by such courts or (c) any litigation or other proceeding commenced in such courts is brought in an inconvenient forum. 

7.13 Computation of Time. Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder will
fall on a Saturday, Sunday, or any public or legal 

  
 11 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 CONFIDENTIAL 

 

 
holiday in New York, New York, or Bermuda, the Party having such privilege or duty will have until 5:00 p.m. Eastern Time on the next succeeding business day to exercise such privilege or to
discharge such duty. 
 7.14 Severability. In the event any provision, clause, sentence, phrase, or word hereof, or the
application thereof in any circumstances, is held to be invalid or unenforceable, such invalidity or unenforceability will not affect the validity or enforceability of the remainder hereof, or of the application of any such provision, sentence,
clause, phrase, or word in any other circumstances. 
 7.15 Costs and Expenses. Unless otherwise provided in this Agreement,
each Party will bear all fees and expenses incurred in performing its obligations under this Agreement. 
 7.16 Meaning in
Notices. Unless a contrary indication appears, a term used in any notice given under or in connection with this Agreement has the same meaning in that notice as in this Agreement. 

[Signature Page Follows] 

  
 12 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 Confidential 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 

 

									
	ROIVANT SCIENCES LTD.	 		 	MYOVANT SCIENCES LTD. 
					
	By:	 	 /s/ Marianne L. Romeo
	 		 	By:	 	 /s/ Marianne L. Romeo

					
	Name:	 	Marianne L. Romeo	 		 	Name:	 	Marianne L. Romeo
					
	Title:	 	Head, Global Transactions & Risk Management	 		 	Title:	 	Head, Global Transactions & Risk Management

  
 13 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406.EX-10.11

 Exhibit 10.11 

EXECUTION VERSION 
 INFORMATION
SHARING AND COOPERATION AGREEMENT 
 This Information Sharing and Cooperation Agreement, dated as of July 6, 2016 (this
“Agreement”), is by and between Roivant Sciences Ltd., a Bermuda exempted company (“Roivant”), and Myovant Sciences Ltd., a Bermuda exempted company
(“Myovant”, with each of Roivant and Myovant, a “Party” and together, the “Parties”).  

RECITALS 
 WHEREAS,
Roivant is the beneficial owner of a majority of the issued and outstanding stock of Myovant; 
 WHEREAS, Roivant and Myovant currently
contemplate that Myovant will engage in an initial public offering (“IPO”) of shares of Myovant’s stock (“Shares”) pursuant to a Registration Statement on Form S-1 filed with the
Securities and Exchange Commission (the “SEC”);  
 WHEREAS, in connection with the IPO, Myovant will apply
to list the Shares for trading on the NASDAQ Stock Market (“NASDAQ”);  
 WHEREAS, Roivant’s
majority ownership of Myovant after the IPO will require Roivant to continue consolidating Myovant’s financial statements with its own under U.S. generally accepted accounting principles (“GAAP”) and SEC reporting
requirements; 
 WHEREAS, the significance of Myovant to Roivant may, under certain circumstances, result in Roivant requiring access to
certain information regarding Myovant even if Roivant ceases to consolidate Myovant’s financial statements with its own; and 

WHEREAS, the Parties intend that this Agreement shall set forth the principal arrangements between Roivant and Myovant regarding the sharing
of information and cooperation of the Parties in connection with the preparation of each Party’s financial statements and, to the extent applicable in the future, their respective reporting obligations under other circumstances, from and after
the date of effectiveness of the Registration Statement for the IPO (the “Effective Date”).  
 NOW,
THEREFORE, in consideration of the foregoing recitals and the covenants and conditions set forth herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties hereto agree as follows.

 ARTICLE I 

FINANCIAL REPORTING AND DISCLOSURE COVENANTS 

Section 1.01 Financial Reporting and Controls. The Parties agree that they will comply with the requirements set forth in this Section
1.01, (A) with respect to Sections 1.01(b), (c), (d), (g), (h) and (j) from and after the Effective Date, and (B) with respect to Sections 1.01(a) through (j), from and after such time that Roivant (i) notifies Myovant that it is actively engaging
in the preparation of a registration statement to be filed under the Securities Act for an initial public offering of its securities or (ii) has a class of securities registered under Section 13(a) or 15(d) of the Exchange Act, in each case. for so
long as Roivant is required (x) by GAAP reporting requirements to consolidate the results of operations and financial position of Myovant, (y) to account for its investment in Myovant under the equity method of accounting (determined in accordance
with GAAP and consistent with SEC reporting requirements), or (z) pursuant to any rule of the SEC that is applicable to Roivant and requires Roivant to include separate financial statements of Myovant in any filing with the SEC. Notwithstanding
anything to the contrary and for further clarification purposes, all covenants of Myovant contained in this Article II of this Agreement will expire and 

  
 1 

 
terminate when Roivant is no longer required by GAAP reporting requirements to consolidate the results of the operations and financial position of Myovant, account for its investment in Myovant
under the equity method of accounting, or otherwise include separate financial statements of Myovant in its filings with the SEC pursuant to any rule of SEC. 

(a) Disclosure of Financial Controls. In connection with the filing of Roivant’s annual and quarterly reports under the Exchange
Act or any investigations of prior periods, Myovant shall cause its principal executive officer and principal financial officer to provide to Roivant (A) on a timely basis, if this provision is applicable by virtue of Section 1.01(x) and (B) on a
timely basis and if reasonably requested by Roivant, if this provision is applicable by virtue of Sections 1.01(y) or (z), (1) certifications to Roivant corresponding to those required under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002,
(2) any certificate that may be reasonably necessary for Roivant to satisfy the requirements applicable to it under Section 404 of the Sarbanes-Oxley Act of 2002, (3) any certificates or other written information that Myovant’s principal
executive officer or principal financial officer received as support for the certificates provided to Roivant and (4) a reasonable opportunity to discuss with Myovant’s principal financial officer and other appropriate officers and employees of
Myovant any issues reasonably related to the foregoing. 
 (b) Quarterly Financial Statements. 

(i) As soon as reasonably practicable and no later than 15 days before the date by which Roivant is required to file a quarterly report on
Form 10-Q if this provision is applicable by virtue of Section 1.0l(x) above or 10 days before the date by which Roivant is required to file a quarterly report on Form 10-Q if this provision is applicable by virtue of Section l.0l(y) or (z) above,
Myovant will deliver to Roivant reasonably complete drafts of (i) the consolidated financial statements of Myovant (and notes thereto) for the quarterly periods and for the period from the beginning of the current fiscal year to the end of such
quarter, setting forth in each case in comparative form for each such fiscal quarter of Myovant the consolidated figures (and notes thereto) for the corresponding quarter and periods of the previous fiscal year prepared in accordance with Article 10
of Regulation S-X and GAAP and (ii) a discussion and analysis by management of Myovant’s financial condition and results of operations for such fiscal period, including, without limitation, an explanation of any material period-to-period change
and any off-balance sheet transactions, prepared in accordance with Item 303(b) of Regulation S-K. The information set forth in (i) and (ii) above is referred to in this Agreement as the “Myovant Quarterly Financial Statements.” As
soon as reasonably possible and no later than 5 days before the date by which Roivant is required to file a quarterly report on Form 10-Q, Myovant will deliver to Roivant the final form of the Myovant Quarterly Financial Statements, provided,
however, that Myovant may continue to revise such Myovant Quarterly Financial Statements prior to its filing thereof in order to make corrections, updates and changes, which corrections, updates and changes, if substantive, will be delivered
by Myovant to Roivant as soon as reasonably possible. At Roivant’s request, Myovant’s representatives will consult and discuss with Myovant’s representatives any such corrections, updates and changes. To the extent that the fiscal
year of Roivant is not the same as the fiscal year of Myovant or Roivant is not subject to reporting obligations under Section 13(a) or l5(d) of the Exchange Act, the obligation to deliver Myovant Quarterly Financial Statements before the date by
which Roivant is required to file its quarterly report on Form 10-Q shall be determined based on the date by which Myovant is required to file its quarterly report on Form 10-Q. 

(ii) As soon as reasonably practicable and no later than 45 days after the end of its fiscal year, Myovant will deliver to Roivant its
consolidated financial statements (and 

  
 2 

 
notes thereto) for the last quarter of its fiscal year, setting forth in each case in comparative form for such fiscal quarter of Myovant the consolidated figures (and notes thereto) for the
corresponding quarter of the previous fiscal year prepared in accordance with Article 10 of Regulation S-X and GAAP; provided, however, that Myovant may continue to revise such financial statements in order to make corrections, updates
and changes in connection with the preparation of its audited annual financial statements, which corrections, updates and changes, if substantive, will be delivered by Myovant to Roivant as soon as reasonably possible. 

(c) Annual Financial Statements. As soon as reasonably practicable and no later than 45 days after the end of its fiscal year if this
provision is applicable by virtue of Section 1.0l(x) above or 55 days after the end of its fiscal year if this provision is applicable by virtue of Section 1.01(y) or (z) above, Myovant will deliver to Roivant reasonably complete drafts of (i) the
consolidated financial statements of Myovant (and notes thereto) for such year, setting forth in each case in comparative form the consolidated figures (and notes thereto) for the previous fiscal years, prepared in accordance with Article 10 of
Regulation S-X and GAAP and (ii) a discussion and analysis by management of Myovant’s financial condition and results of operations for such year, including, without limitation, an explanation of any material period-to-period changes and any
off-balance sheet transactions, prepared in accordance with Item 303(a) and 305 of Regulation S-K. The information set forth in (i) and (ii) above is referred to in this Agreement as the “Myovant Annual Financial
Statements.” As soon as reasonably possible and no later than 15 days before the date by which Roivant is required to file its annual report on Form 10-K if this provision is applicable by virtue of Section 1.01(x)
above or 10 days before the date by which Roivant is required to file its annual report on Form 10-K if this provision is applicable by virtue of Section 1.0l (y) or (z) above, Myovant will deliver to Roivant the final form of the Myovant
Annual Financial Statements and an opinion on the Myovant Annual Financial Statements by Myovant’s independent registered public accountants (the “Myovant Auditors”); provided, however, that Myovant may, if
necessary, continue to revise such Myovant Annual Financial Statements prior to the filing thereof in order to make corrections, updates and changes, which corrections, updates and changes, if substantive, will be delivered by Myovant to Roivant as
soon as reasonably possible. At Roivant’s request, Myovant’s representatives will consult and discuss with Roivant’s representatives any such corrections, updates and changes. To the extent that the fiscal year of Roivant is not the
same as the fiscal year of Myovant or Roivant is not subject to reporting obligations under Section 13(a) or 15(d) of the Exchange Act, the obligation to deliver Myovant Annual Financial Statements before the date by which Roivant is required to
file its annual report on Form 10-K shall be determined based on the date by which Myovant is required to file its quarterly report on Form 10-K. 

(d) Conformance of Financial Statements. Subject to the other terms in this Agreement, Myovant shall not make or adopt any significant
changes to its accounting estimates or accounting policies and principles from those in effect on the Effective Date to the extent that such changes would significantly impact Roivant’s financial statements. Notwithstanding the previous
sentence, nothing in this Agreement shall prevent Myovant making those changes to its accounting estimates or accounting policies and principles if such changes are required by GAAP or which the audit committee of Myovant determines are necessary or
appropriate for the proper presentation of such Party’s financial statements; provided, however, that Myovant shall first consult with Roivant and, if requested by Roivant, with Roivant’s independent certified public
accountants. 
 (e) Press Releases and Similar Information. Myovant and Roivant will consult with each other as to the timing of
their annual and quarterly earnings releases and any interim financial guidance for a current or future period and, to the extent reasonably possible. If the Parties are unable to agree as to such timing, then Roivant and Myovant shall each make

  
 3 

 
reasonable efforts to issue their respective annual and quarterly earnings releases at approximately the same time on the same date, which will include for these purposes during the same period
of time beginning after the close of market on one day and ending just prior to the opening of market on the next day. Roivant and Myovant agree to consult with each other as to the timing of their respective earnings release conference calls. 

(f) Cooperation on Roivant Filings. Myovant agrees to provide to Roivant, and to instruct the Myovant Auditors to provide to Roivant,
all material information with respect to Myovant that Roivant reasonably requires in connection with the preparation by Roivant of its Quarterly Reports on Form10-Q. Annual Reports to Shareholders, Annual Reports on Form 10-K, any Current Reports on
Form 8-K and any registration statements, or other filings made by Roivant with the SEC, any national securities exchange or otherwise made publicly available with respect to the disclosures pertaining to Myovant (collectively, the
“Roivant Public Filings”). The Parties agree to reasonably cooperate with each other with respect to the requesting and furnishing of such required information in order to enable Roivant to file all Roivant Public
Filings within the deadlines as required by applicable law. Myovant will cause the Myovant Auditors (as defined below) to consent to any reference to them as experts in any Roivant Public Filings required under any law, rule or regulation. 

(g) Access to the Myovant Auditors. Myovant will authorize the Myovant Auditors to make reasonably available to the Roivant Auditors
both the personnel who performed, or are performing, the annual audit and quarterly reviews of Myovant and work papers related to the annual audit and quarterly reviews of Myovant, in all cases within a reasonable time prior to the Roivant Auditors
opinion date, so that the Roivant Auditors are able to perform the procedures they consider necessary to take responsibility for the work of the Myovant Auditors as it relates to the Roivant Auditors’ report on Roivant’s statements. 

(h) Access to Records. If Roivant determines in good faith that there may be a material inaccuracy in Myovant’s financial
statements or deficiency or inadequacy in Myovant’s internal accounting controls or operations that could reasonably be expected to materially impact Roivant’s financial statements, and at Roivant’s request, Myovant will provide
Roivant’s internal auditors with reasonable access to Myovant’s books and records so that Roivant may conduct reasonable audits relating to the financial statements provided by Myovant under this Agreement, as well as to the internal
accounting controls and operations of Myovant. 
 (i) Provision of Information. Myovant shall provide, or cause to be provided, to
Roivant, as soon as reasonably practicable after request therefor, confirmation as to whether Myovant is in possession of information that would reasonably be considered to be material nonpublic information with respect to Myovant under applicable
U.S. securities laws, and sufficient additional information as is necessary, in the reasonable judgment of Roivant and its counsel, to determine whether such information is material with respect to Roivant under applicable U.S. securities laws. 

(j) Fiscal Year. Myovant shall not change its fiscal year without the prior written consent of Roivant. 

  
 4 

 ARTICLE II 

EXCHANGE OF INFORMATION: CONFIDENTIALITY 

Section 2.01 Privilege. In the event that Myovant reasonably determines that the provision of information pursuant to this Agreement
would violate any law or bona fide contractual restriction, or result in the waiver of any Privilege, the Parties shall take all commercially reasonable measures to permit the compliance with the provision of information obligations in a manner that
avoids any such harm or consequence, which shall include, but not be limited to, compliance with Sections 2.05, 2.06 and 2.07 hereof. For purposes of this Agreement, the term “Privilege” shall mean information and advice that
has been previously developed but is legally protected from disclosure under legal privileges, such as the attorney-client privilege, work product exemption or similar concept of legal protection. 

Section 2.02 Ownership of Information. Any information owned by Myovant that is provided to Roivant pursuant to the terms of this
Agreement shall be deemed to remain the property of Myovant. Unless expressly set forth in this Agreement, nothing contained in this Agreement shall be construed as granting or conferring any right, title or interest (whether by license or
otherwise) in, to, or under any such information. 
 Section 2.03 Record Retention. To facilitate the provision of information
pursuant to this Agreement after the Effective Date. Myovant, agrees to retain all information in its possession or control on Effective Date in accordance with its document retention policies, as such policies may be reasonably amended or revised
after the Effective Date. Myovant shall provide Roivant with reasonable notice of any material amendment or revision to its retention policies after the Effective Date. Myovant shall not materially amend or revise its retention policy in effect at
the time of its IPO for a period of three years after the IPO. 
 Section 2.04 Limitations of Liability. Myovant shall have no
liability to Roivant in the event that any information exchanged or provided pursuant to this Agreement is found to be inaccurate or the requested information is not provided, in the absence of willful misconduct by, or gross negligence of Myovant.
Myovant shall not have any liability to Roivant if any information is destroyed in compliance with its document retention policies. 

Section 2.05 Confidentiality. 

(a) Subject to Section 2.07, Roivant agrees to hold, and to cause its respective directors, officers, employees, agents, accountants,
counsel and other advisors and representatives, including for the avoidance of doubt underwriters or other parties providing financing to Roivant, to hold in strict confidence, with at least the same degree of care that applies to its confidential
and proprietary information pursuant to its policies in effect as of the Effective Date, all information with respect to Myovant that is accessible to it, in its possession (including information in its possession prior to the Effective Date) or
furnished by Myovant, or accessible to, in the possession of, or furnished to Roivant pursuant to this agreement or otherwise, except, in each case, to the extent that such information (i) is or becomes part of the public domain through no breach of
this Agreement by Roivant or its directors, officers, employees, agents, accountants, counsel and other advisors and representatives, (ii) was independently developed following the Effective Date by employees or agents of Roivant or its directors,
officers, employees, agents, accountants, counsel and other advisors and representatives who have not accessed or otherwise received the applicable information; provided that such independent development can be demonstrated by
competent, contemporaneous written records of Roivant, (iii) becomes available to Roivant following the Effective Date on a non-confidential basis from a third party who is not bound directly or indirectly by a duty of confidentiality to Myovant; or
(iv) is provided by Myovant and appropriately disclosed by Roivant in accordance with the terms of Article I. 

  
 5 

 (b) The Parties acknowledge that they may have in their possession confidential or proprietary
information of third Parties that was received under confidentiality or non-disclosure agreements with such third Party. The Parties will hold in strict confidence the confidential and proprietary information of third Parties to which they have
access in accordance with the terms of any such agreements. 
 (c) Notwithstanding anything herein to the contrary, following the Effective
Date, Roivant shall be permitted to (i) use the Myovant trademark in its written materials when referencing Myovant, (ii) provide confidential information regarding Myovant (including but not limited to historical financial and other
information) to persons who have a legitimate reason to know such information and who are under an obligation to keep such information confidential, and (iii) publish non-confidential information of Myovant (including but not limited to historical
financial and other information). 
 (d) Notwithstanding anything to the contrary in this Article III, Roivant shall have no right to use
any information disclosed by Myovant unless otherwise provided for in this Agreement or specifically provided for in any other agreement between the Parties. 

Section 2.06 Protective Arrangements. In the event that Roivant either determines on the advice of its counsel that it is required to
disclose any information pursuant to applicable law (including the rules and regulations of the SEC in connection with any proposed registration of Roivant’s securities under the Securities Act of 1933, as amended (the
“Securities Act”) or the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or pursuant to the requirements of any national securities exchange) or receives any request or demand
from any governmental authority to disclose or provide information of Myovant that is subject to the confidentiality provisions hereof. Roivant shall notify Myovant prior to disclosing or providing such information and shall cooperate at the expense
of Roivant in seeking any reasonable protective arrangements (including by seeking confidential treatment of such information) requested by Myovant. Subject to the foregoing, Roivant may thereafter disclose or provide information to the extent
required by such law (as so advised by counsel) or requested or required by such governmental authority; provided, however, that Roivant provides Myovant, to the extent legally permissible, upon request with a copy of the information
so disclosed. 
 Section 2.07 Preservation of Legal Privileges. 

(a) The parties recognize that they possess and will possess Privileged information. Each Party recognizes that they shall be jointly entitled
to the Privilege with respect to such Privileged information and that each shall be entitled to maintain, preserve and assert for its own benefit all such information and advice, but both Parties shall ensure that such information is maintained so
as to protect the Privileges with respect to the other Party’s interest. To that end, neither Party will knowingly waive or compromise any Privilege associated with such information and advice without the prior written consent of the other
Party, which shall not be unreasonably withheld. In the event that Privileged information is required to be disclosed to any arbitrator or mediator in connection with a dispute between the Parties, such disclosure shall not be deemed a waiver of
Privilege with respect to such information, and any Party receiving it in connection with a proceeding shall be informed of its nature and shall be required to safeguard and protect it. 

(b) Upon receipt by either Party of any subpoena, discovery or other request that may call for the production or disclosure of information
that is the subject of a Privilege, or if a 

  
 6 

 
Party obtains knowledge that any current or former employee of a Party has received any subpoena, discovery or other request that may call for the production or disclosure of such information,
such Party shall provide the other Party a reasonable opportunity to review the information and to assert any rights it may have under this Section 2.07 or otherwise to prevent the production or disclosure of such information. Absent receipt of
written consent from the other Party to the production or disclosure of information that may be covered by a Privilege, each Party agrees that it will not produce or disclose any information that may be covered by a Privilege unless a court of
competent jurisdiction has entered a final, nonappealable order finding that the information is not entitled to protection under any applicable Privilege. 

ARTICLE III 
 TAX
MATTERS 
 Section 3.01 PFIC. For so long as Roivant owns stock of Myovant, Myovant will use reasonable best efforts to
avoid, in respect of any taxable year, being treated as a passive foreign investment company (“PFIC”) within the meaning of Section 1297 of the Code, including, but not limited to, causing any of its subsidiaries to
file an election pursuant to Treasury Regulation Section 301.7701-3. No later than 75 days after the end of each taxable year. Myovant shall deliver to Roivant an analysis as to whether Myovant believes
that it will be treated as a PFIC in respect of such taxable year. Such analysis may be prepared by Myovant, but in preparing such analysis Myovant shall consult with its internationally recognized tax advisors. 

Section 3.02 OEF Information. Myovant shall use reasonable best efforts to provide, and shall cause each of its subsidiaries to use
reasonable best efforts to provide, to Roivant all information that may be necessary to allow Roivant, and any direct or indirect owners of Roivant, to evaluate the analysis referenced in Section 3.01 and to fulfill their U.S. tax filing and
reporting obligations. Myovant shall provide, and shall cause each of its subsidiaries to provide, such information to Roivant, and any direct or indirect owners of Roivant, as may reasonably be required to timely file and maintain a “qualified
electing fund” election (as defined in Section 1295(a) of the Code) with respect to any such entity. 
 Section 3.03 No Passive
Income. For a period of six months after the consummation of the IPO, Myovant shall invest its cash and cash equivalents in a non-interest bearing account and will not otherwise generate “passive income” within the meaning of
Section 1297(b) of the U.S. Internal Revenue Code of 1986, as amended. 
 ARTICLE IV 

DISPUTE RESOLUTION 

Section 4.01 Limitation on Monetary Damages: Equitable Remedies. Myovant and Roivant hereby agree that neither Party shall have any
liability for monetary damages for any breach of this Agreement so long as such Party used commercially reasonable efforts to comply with the obligation such Party breached and continues thereafter to use commercially reasonable efforts to remedy
such breach. In addition to other remedies provided by applicable law. Myovant and Roivant may each enforce the provisions of this Agreement through such legal or equitable remedies as a court of competent jurisdiction shall allow without the
necessity of proving actual damages or bad faith, and the Party subject to a claim under this Agreement hereby waives any claim or defense that such Party has an adequate remedy at law, and waives any requirement for the securing or posting of any
bond in connection with such equitable remedy. 

  
 7 

 Section 4.02 Disputes. The procedures for discussion, negotiation and mediation set forth
in this Article V shall apply to all disputes, controversies or claims (whether arising in contract, tort or otherwise) that may arise out of or relate to, or arise under or in connection with, this Agreement or the transactions contemplated hereby
or thereby (including all actions taken in furtherance of the transactions contemplated hereby on the Effective Date). Myovant hereby agrees that its members of the board of directors or senior management that are not affiliated with Roivant shall
lead all discussions, negotiations and mediations that occur pursuant to this Article V. 
 Section 4.03 Escalation; Mediation.

 (a) It is the intent of the Parties to use their respective commercially reasonable efforts to resolve expeditiously any dispute,
controversy or claim between or among them with respect to the matters covered by this Agreement. In furtherance of the foregoing, any Party involved in a dispute, controversy or claim with respect to such matters may deliver a notice (an
“Escalation Notice”) demanding an in person meeting involving representatives of the Parties at a senior level of management of the Parties (or if the Parties agree, of the appropriate strategic business unit or
division within such entity). A copy of any such Escalation Notice shall be given to the general counsel, or like officer or official, of each Party involved in the dispute, controversy or claim (which copy shall state that it is an Escalation
Notice pursuant to this Agreement). Any agenda, location or procedures for such discussions or negotiations between the Parties may be established by the Parties from time to time; provided, however, that the Parties shall use their
commercially reasonable efforts to meet within 30 days of the Escalation Notice. 
 (b) If the Parties are not able to resolve the dispute,
controversy or claim through the escalation process referred to above, then the matter shall be referred to mediation. The Parties shall retain a mediator to aid the Parties in their discussions and negotiations by informally providing advice to the
Parties. Any opinion expressed by the mediator shall be strictly advisory and shall not be binding on the Parties, nor shall any opinion expressed by the mediator be admissible in any other proceeding. The mediator may be chosen from a list of
mediators previously selected by the Parties or by other agreement of the Parties. Costs of the mediation shall be borne equally by the Parties involved in the matter, except that each Party shall be responsible for its own expenses. Mediation shall
be a prerequisite to the commencement of any action by either Party. 
 Section 4.04 Court Actions. 

(a) In the event that any Party, after complying with the provisions set forth in Section 4.03 above, desires to commence an action, such
Party, subject to Section 6.15, may submit the dispute, controversy or claim (or such series of related disputes, controversies or claims) to any court of competent jurisdiction as set forth in Section 6.15. 

(b) Unless otherwise agreed in writing, the Parties will continue to provide service and honor all other commitments under this Agreement
during the course of dispute resolution pursuant to the provisions of this Article IV, except to the extent such commitments are the subject of such dispute, controversy or claim. 

  
 8 

 ARTICLE V 

FURTHER ASSURANCES 

Section 5.01 Further Assurances. 

(a) In addition to the actions specifically provided for elsewhere in this Agreement, each of the Parties hereto will cooperate with each
other and shall use their commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things, reasonably necessary, proper or advisable under applicable laws, regulations and agreements to
consummate and make effective the transactions contemplated by this Agreement. 
 (b) Without limiting the foregoing, prior to, on and after
the Effective Date, each Party hereto shall cooperate with the other Party, and without any further consideration, but at the expense of the requesting Party, to execute and deliver, or use its commercially reasonable efforts to cause to be executed
and delivered, all instruments, including instruments of conveyance, assignment and transfer, and to make all filings with, and to obtain all consents, approvals or authorizations of, any governmental authority or any other person or entity under
any permit, license, agreement, indenture, order, decree, financial assurance (including letter of credit) or other instrument, and to take all such other actions as such Party may reasonably be requested to take by such other Party hereto from time
to time, consistent with the terms of this Agreement. 
 (c) Nothing in this Agreement shall be construed to restrict or limit any right,
responsibility or authority of either of Parties hereto or their respective, independent registered public accountants, audit committee or board of directors in violation of any law, legal requirement or listing standard applicable to such Party,
whether existing today or hereafter. In the event either Party hereto reasonably determines that any provision in this Agreement does or will so limit any right, responsibility or authority of such Party or such Party’s independent registered
public accountants, audit committee or board of directors, then the Parties hereto agree to attempt to negotiate in good faith any changes necessary or advisable to this Agreement to avoid or prevent such violation. 

ARTICLE VI 

MISCELLANEOUS 

Section 6.01 Counterparts; Entire Agreement; Conflicting Agreements. 

(a) This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become
effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party. Execution of this Agreement or any other documents pursuant to this Agreement by facsimile or other electronic transmission shall be
deemed to be, and shall have the same effect as, executed by an original signature. 
 (b) This Agreement contains the entire agreement of
the Parties with respect to the subject matter hereof, supersede all previous agreements, negotiations, discussions, writings, understandings, commitments and conversations with respect to such subject matter and there are no agreements or
understandings between the Parties with respect to such subject matter other than those set forth or referred to herein or therein. 
 (c)
In the event and to the extent that there shall be a conflict between the provisions of this Agreement and the provisions of any other agreement between the Parties, the other agreement shall control with respect to the subject matter thereof, and
this Agreement shall control with respect to all other matters. 

  
 9 

 Section 6.02 No Construction Against Drafter. The Parties acknowledge that this Agreement
and all the terms and conditions herein have been fully reviewed and negotiated by the Parties and their respective attorneys. Having acknowledged the foregoing, the Parties agree that any principle of construction or rule of law that provides that,
in the event of any inconsistency or ambiguity, an agreement shall be construed against the drafter of the agreement shall have no application to the terms and conditions of this Agreement. 

Section 6.03 Governing law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of the State
of New York, without regard to the conflict of laws principles thereof that would result in the application of any law other than the laws of the State of New York. 

Section 6.04 Assignability. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective
successors and permitted assigns; provided, however, that no Party may assign its respective rights or delegate its respective obligations under this Agreement without the express prior written consent of the other Party. 

Section 6.05 Notices. All notices and other communications required or permitted hereunder to be given to a party to this Agreement
shall be in writing and shall be transmitted via facsimile or email or mailed by registered or certified mail, postage prepaid, or otherwise delivered by hand or by messenger, addressed to such party’s address as set forth below or at such
other address as the party shall have furnished to each other party in writing in accordance with this provision. 
 If to Roivant, to: 

Roivant Sciences Ltd 
 Clarendon
House 
 2 Church Street 

Hamilton HM11 
 Bermuda 

Attention: Corporate Secretary 

Facsimile: +1 (441) 292 4720 

Email: info@roivant.com 
 with a
copy sent concurrently to: 
 Roivant Sciences, Inc 

320 West 37th Street, 5th Floor 

New York, NY 10018 
 Attention:
Alan S. Roemer, SVP, Business Operations 
 Facsimile: (212) 202-4650 

Email: alan.roemer@roivant.com 

If to Myovant to: 
 Myovant
Sciences Ltd. 
 Clarendon House 

2 Church Street 
 Hamilton HM11

  
 10 

 Bermuda 

Attention: Corporate Secretary 

Facsimile: +1 (441) 292 4720 

Email: info@roivant.com 
 with a
copy sent concurrently to: 
 Myovant Sciences, Inc. 

320 West 37th Street, 5th Floor 

New York, NY 10018 
 Attention:
Allan S. Roemer 
 Facsimile: (212) 202 4650 

Email: alan.roemer@roivant.com 

Any Party may, by notice to the other Party, change the address to which such notices are to be given. 

Any notice sent in accordance with this Section 6.05 shall be effective (i) if mailed, 7 Business Days after mailing, (ii) if sent by
messenger, upon delivery, and (iii) if sent via facsimile or email, upon transmission and electronic confirmation of receipt or (if transmitted and received on a non-Business Day) of the first Business Day following transmission and electronic
confirmation of receipt (provided, however, that any notice of change of address shall only be valid upon receipt). A “Business Day” shall mean any day other than a Saturday or Sunday or any other day on which banks in the State of New
York are required or permitted by law to close. 
 Section 6.06 Severability. if any provision of this Agreement or the application
thereof to any person or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof or the application of such provision to persons or circumstances or in jurisdictions other
than those as to which it has been held invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby so long as the economic or legal substance of the transactions contemplated
hereby is not affected in any manner adverse to any Party. Upon such determination, the Parties shall negotiate in good faith in an effort to agree upon such a suitable and equitable provision to effect the original intent of the Parties 

Section 6.07 Force Majeure. No Party shall be deemed in default of this Agreement to the extent that any delay or failure in the
performance of its obligations under this Agreement results from any cause beyond its reasonable control and without its fault or negligence, such as acts of God, acts, or civil or military authority, embargoes, epidemics, war, riots, insurrections,
fires, explosions, earthquakes, floods, unusually severe weather conditions or labor problems. In the event of any such excused delay, the time for performance shall be extended for a period equal to the time lost by reason of the delay. 

Section 6.08 Headings. The article, section and paragraph headings contained in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. 
 Section 6.09 Termination: Survival. This Agreement
and all covenants and obligations herein terminate upon the earlier of (i) written consent of Myovant and Roivant, or (ii) when Roivant is no longer required by GAAP reporting requirements to consolidate the results of the operations and financial
position of Myovant, account for its investment in Myovant under the equity method of accounting or otherwise include separate financial statements of Myovant in its 

  
 11 

 filings with the SEC pursuant to any rule of SEC; provided, however, Sections 2.02, 2.04, 2.05,
2.06, 2.07, Article V, Article VI, and Article VII of this Agreement shall remain in full force and effect following any termination of this Agreement. 

Section 6.10 Waivers of Default. Waiver by any Party of any default by the other Party of any provision of this Agreement shall not be
deemed a waiver by the waiving Party of any subsequent or other default, nor shall it prejudice the rights of the other Party. 
 Section
6.11 Specific Performance. In the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement, the Party or Parties who are or are to be thereby aggrieved shall have the right
to specific performance and injunctive or other equitable relief of its rights under this Agreement, in addition to any and all other rights and remedies at law or an equity, and all such rights and remedies shall be cumulative. 

Section 6.12 Amendments. No provisions of this Agreement shall be deemed waived, amended, supplemented or modified by any Party, unless
such waiver, amendment, supplement or modification is in writing and signed an authorized representative of the Party against whom it is sought to enforce such waived amendment, supplement or modification. 

Section 6.13 Interpretation. Words in the singular shall be held to include the plural and vice versa and words of the gender
shall be held to include the other genders as the context requires. The terms “hereof”, “herein” and “herewith” and words of similar import shall, unless otherwise stated, or construed to refer to this Agreement as a
whole and not to any particular provision of this Agreement. Article and Section references are to the Articles and Sections to this Agreement unless otherwise specified. The word “including” and words of similar import when used in this
Agreement shall mean “including, without limitation,” unless the context otherwise requires or unless otherwise specified. 

Section 6.14 Waiver of Jury Trial. SUBJECT TO ARTICLE V AND SECTIONS 6.10 AND 6.11 HEREIN, EACH OF THE PARTIES HEREBY WAIVES TO THE
FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY COURT PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF AND PERMITTED UNDER OR IN CONNECTION WITH THIS AGREEMENT OF THE TRANSACTIONS CONTEMPLATED
BY THIS AGREEMENT. EACH OF THE PARTIES HEREBY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE
FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS. THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 7.14. 

Section 6.15 Submission to Jurisdiction; Waivers. With respect to any action relating to or arising out of this Agreement subject to
the provisions of Article V, each Party to this Agreement irrevocably (a) consents and submits to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan, The City of the New York; (b) waives any
objection which such Party may have at any time to the laying of venue of any action brought in any such court, waives any claim that such action has been brought in an inconvenient forum and further waives the right to object with respect to such
action that such court does not have jurisdiction over such Party and (c) consents to the service of process at the address set forth for notices in Section 7.05 herein; provided, however, that such manner of service of process shall
not preclude the service of process in any other manner permitted under applicable law. 

  
 12 

 Section 6.16 No Third-Party Beneficiaries. This Agreement is not intended, nor shall it be
deemed, to confer any rights or remedies on any person other than the Parties hereto and their respective successors and assigns. This Agreement does not create any third-party beneficiary hereto and Myovant and Roivant are the only parties entitled
to commence any action, proceeding or claim under this Agreement. 
 Section 6.17 Expenses. Each Party is responsible for its own
fees, costs and expenses incurred in connection with this Agreement and the activities contemplated hereby; provided, further, to the extent that the observation of the covenants and performance of the obligations set forth in Article
II result in additional significant financial expenses to Myovant, upon Myovant’s request, the Parties will discuss potential reimbursement by Roivant with respect to such additional financial expenses incurred by Myovant. 

[Signature page immediately follows.] 

  
 13 

 IN WITNESS WHEREOF, the Parties have caused this Information Sharing and Cooperation Agreement to
be executed by their duly authorized representatives as of the date first set forth above. 
  

					
	ROIVANT SCIENCES LTD.
		
	By:	 	/s/ ILAN OREN
		 	Name:	 	ILAN OREN
		 	Title:	 	Director
	
	MYOVANT SCIENCES LTD.
		
	By:	 	/s/ MARIANNE L. ROMEO
		 	Name:	 	MARIANNE L. ROMEO
		 	Title:	 	Head, Global Transactions & Risk Management

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]